Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

Q1 2019 Earnings Call
Company Participants
FINAL

Antonio Cano Y Bosque, Chief Operating Officer and Executive Director
Bart De Smet, Chief Executive Officer and Executive Director
Christophe Boizard, Chief Financial Officer and Executive Director
Hans J. J. De Cuyper, Chief Executive Officer and Director

Other Participants
Albert Ploegh, Analyst
Ashik Musaddi, Analyst
Bart Jooris , Analyst
Farooq Hanif , Analyst
Jason Kalamboussis , Analyst
Matthias De Wit, Analyst
Robin van den Broek, Analyst

Bloomberg Transcript

Presentation
Operator
Ladies and gentlemen, welcome to the Ageas Conference Call for the first three months
of 2019. I am pleased to present Mr. Bart De Smet, Chief Executive Officer; Mr. Christophe
Boizard, Chief Financial Officer; Mr. Filip Coremans, Chief Risk Officer; Mr. Antonio Cano,
Chief Operating Officer; and Mr. Hans De Cuyper, CEO Belgium. For the first part of this
call, let me warn you that's all participant will remain on listen-only mode. And afterwards
there will be a Q&A session. Please also note that this conference is being recorded.
I would like to hand the call over to Mr. Bart De Smet, CEO, and Mr. Christophe Boizard,
CFO. Gentlemen, please go ahead.

Bart De Smet

{BIO 16272635 <GO>}

Good morning, ladies and gentlemen. Thank you all for dialing into this conference call
and for being with us for the presentation of the results of Ageas for the first three
months of 2019. I'm joined by my colleagues of the executive committee and by Hans De
Cuyper, CEO of AG Insurance, and of course, our Investor Relations team is here as well.
Ladies and gentlemen, before commenting on the results of the quarter, I would like to
highlight a few developments that have occurred in the past month. On the M&A front,
we completed the acquisition of 40% of the Indian Non-Life company, Royal Sundaram
Page 1 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

FINAL

General Insurance. Furthermore, as announced, we launched the quota share reinsurance
program for the Non-Life activities within the group with the aim to enhance capital
fungibility. This internal reinsurance program is now up and running in Belgium, UK and
Portugal, and this has at this moment a very limited influence on the net result at group
level, but it has created some internal movements between the different segments
including one-off impacts this quarter. Christophe will come back on this.
Additionally, we announced last month changes in the Executive Committee in order to
best support the AGS' Connect21 ambitions. Filip Coremans will become AGS' First Chief
Development Officer while subject to the approval of the general shareholders' meeting
taking place this afternoon. Emmanuel Van Grimbergen, our Group Risk Officer, will
succeed Filip as Chief Risk Officer.
And on the capital management front, AG has called its $550 million bond in March, and
thanks to its new A level rating AGS was able to successfully issue a EUR500 million Tier-2
debt security last month. It was a great achievement as it was the first time that AGS
issued that at a Holding level.

Bloomberg Transcript

The group net results, which amounted to EUR251 million in this first quarter is in line with
the strong results delivered last year. This year, we suffered again from adverse weather
in Belgium with storms in March. We had a lower capital gains contribution in Belgium, but
this was offset at group level by an exceptionally high result in Asia; thanks to the
favorable equity markets.
We enjoyed solid sales momentum with inflows up 8% and growth in almost all the
segments and the increase was particularly noticeable in Belgium where inflows were up
as much as 34% mostly driven by the sales of Life products, both in Guaranteed and unitlinked. The Guaranteed margin of the group remains within our target range, although it
suffered from a timing difference in the realization of capital gains, plus last year, the
margin benefited from exceptionally high investment income.
The unit link margin was impacted by commercial costs related to the sales campaign in
Belgium and lower sales when compared to Europe. Our combined ratio stood at 98.3%
compared to 98.8% last year and was impacted by the storms in Belgium. Excluding this,
the operating performance was strong across the group.
The new reinsurance program creates some distortions in the combined ratios of the
segments as we've realized the loss portfolio transfer to premium transfer, but as
agreed, we provided you with pro forma ratios in the investor presentation and in the
Excel file that you can find on our website.
Our total liquid assets amounted to EUR1.5 billion compared to the EUR1.7 billion at the
end of 2018. This decrease is mainly attributable to the EUR185 million acquisition in India.
Regarding the cash upstream, by the end of the quarter, we had received EUR75 million
from Portugal and EUR10 million from Turkey. Since the end of Q1, we also received
EUR450 million upstream from Belgium. And as you can see on Slide 5 of the
presentation, we expect to receive the full year at least EUR630 million from the
Page 2 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

insurance operations. This would be more than sufficient to cover the EUR440 million
dividend that we would pay out to our shareholders later this month after approval at the
meeting this afternoon.

FINAL

Ladies and gentlemen, I will now hand over to Christophe for more details on the results.

Christophe Boizard

{BIO 15390084 <GO>}

Thank you, Bart, and good morning, ladies and gentlemen. As usual, I will give you some
details per segment. On Slide 6 on the presentation, so in Belgium, the net result
amounted to EUR81 million compared to EUR136 million last year. As you know, with the
weight of real estate in the investment portfolio, the level of realized capital gains in the
quarter is volatile and depends on the timing of the transactions. This quarter, the results
in Belgium reflects lower capital gain, but let just remember that the level of last year was
very high. More capital gains in real estate are scheduled later in the year and there is no
concern today on realizing the annual budget.

Bloomberg Transcript

In Non-Life, the windstorms that took place in March had an impact of EUR18 million, which
means 10 percentage points on the combined ratio. Excluding this impact, the operating
performance was strong across most business lines. For comparison purpose, please
note that the combined ratio of 104.2% is before the effect of the internal quota shares
where things are comparable with the combined ratio of last year.
On the whole Non-Life pension book, the new quota share reinsurance agreement had a
EUR10 million positive net impact and I strongly advise you to refer to the website where a
detailed tables by segment are provided to explain the accounting effects of the quota
share.
In Life, the Guaranteed operating margin has also suffered a bit [ph] from the lower level
of capital gains, but we are within the target range of 85 bps to 95 bps. The unit-linked
margin was below target mostly due to commercial costs related to the sales campaign
that took place in the first quarter.
As mentioned by Bart, our activity in Belgium benefited from exceptional sales
momentum. The Life inflow jumped by 54% with strong increases in both Guaranteed and
unit-linked products, while Non-Life gross inflows increased by 5% across all business
lines.
In the UK, Slide 7, the result amounted to EUR11 million, at the same level of last year, but
after the EUR12 million of restructuring costs not included in the combined ratio, and a
EUR3 million negative impact from the new internal reinsurance. Inflows were down
reflecting the ongoing pricing discipline. While the Broker channel is the predominant
distribution channel in our book, direct sales through the aggregator platforms continue to
grow in line with our strategy. The combined ratio stood at 95.5% before internal
reinsurance. The lower benefit from prior NEP [ph] was offset by a strong current year
claims ratio performance supported by benign weather.

Page 3 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

FINAL

In Continental Europe, Slide 8, the result was up 27% scope-on-scope; thanks to a strong
performance in Portugal, both in Life and Non-Life. Additionally, the new reinsurance
agreement had EUR3 million positive impact on the result of this segment. Gross inflows
were up 14% scope-on-scope driven in Life by higher sales of Guaranteed products in all
countries and in Non-Life by Household and Healthcare.
In Asia, Slide 9, the exceptionally high result was mainly driven by a high level of capital
gains following the well-performing Chinese equity market, strong investment income and
a solid operating performance across the region. The third dynamic continued in Asia with
strong regular premium in new business and high levels of persistency across the region.
In the reinsurance segment, on Slide 10, an initial loss of EUR12 million following the
implementation of the new internal reinsurance agreements, whose impact was EUR15
million expected to reduce in the coming quarters.

Bloomberg Transcript

The General Account, Slide 11, generated a negative net result of EUR7 million only; thanks
to a sizable positive contribution of the RPN(i) revaluation. This big support was partly
offset by higher costs related to the administrative execution of the Fortis settlement. This
quarter, the provision for the settlement was reduced to EUR764 million compared to
EUR812 million at the end of last year following payments made to shareholders by the
foundation for settlement.
On group Solvency II ratio, Slide 12, the solvency ratio decreased from 215% at year-end
2018 to 194% remaining however very strong and largely above our target of 175%. Some
explanation on this decrease now. 10 percentage points of the decrease is explained by
the call of AG of its $550 million bonds in March. But as Bart mentioned, AGS has since
issued EUR500 million debt security in April, which will bring a 13 percentage points of
solvency in Q2. Second element of explanation; the joint venture in India has caused in
solvency of about 5 percentage points and the rest was explained by the evolution of the
financial markets. The main driver on the quarterly market movement is a sharp drop in
yield curve primarily affecting the own funds of the Life businesses.
The operational free capital generation for Q1 and after isolating the exceptionals, the
impact of the implementation of the internal reinsurance amounted to EUR148 million, as
you can see on Slide 15, of which EUR138 million coming from the Solvency II scope
companies and EUR10 million from the dividend coming from our non-consolidated
partnership in Turkey.
So we can conclude that we're on track with our EUR500 million to EUR540 million guide
yearly -- full year guidance for the Solvency II scope companies. The implementation of
the new internal reinsurance agreements associated with the discontinuation of the stoploss between the UK and the Holding had an exceptional impact of EUR95 million on the
free capital generation, with negative contribution to the free capital generation comes
on the one hand from the termination of the stop-loss for EUR25 million, which is seen as
redundant with the implementation of the quota share and for the rest from an increase
of the SCR related to lower consolidated LACDT. Ladies and gentlemen, I leave now the
room for questions.

Page 4 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

Questions And Answers
Operator

FINAL

Ladies and gentlemen, this concludes the introduction and we now open the call for
questions. (Operator Instructions) The first question is from Jason Kalamboussis from KBC
Securities. Please go ahead.

Q - Jason Kalamboussis

Yes. Good morning. A couple of questions, the first one is on the Asia. You had a very
strong quarter even if we account for seasonality and realized gains. So could you give us
a bit more color on this, that would be great. And also if something that you see already
continuing in the second quarter, again seasonality being accounted in there. The second
thing is on the UK, when do you see the end -- I mean, the inflows are still weak. Would
you see an end to it, because I thought that was something that would start to stabilize
towards the first half of this year? And a final quick one, if I may, on the negative EUR95
million that we had in reinsurance -- due to the internal reinsurance on the free capital
generation, is it -- should we be expecting higher -- other higher SCRs going forward on
the back of this internal reinsurance or it is an exceptional one-off of EUR95 million and it
should stay at these levels? Thanks very much.

A - Bart De Smet

Bloomberg Transcript

{BIO 4811408 <GO>}

{BIO 16272635 <GO>}

Okay I'll take the first question; Antonio, the UK question; and Christophe, the last one. So
on Asia, a strong quarter indeed, but -- and which we could say the most volatile element
in it is of course the capital gains where we had a huge impact in Q4, a negative one from
impairments according to our rules. We have now seen the effect the other way around.
But if you exclude that, I mean, look to the underlying results in all of the countries, we can
clearly say that they all are going in the opposite direction, thanks to of course increased
volumes and so let's say attention to the underlying cost and value of the new business. In
all countries, the value of new business goes up, so that's a positive sign. So I would say
the only uncertainty is the evolution of the equity markets.

A - Antonio Cano Y Bosque
Yes. Hello, good morning. On the UK, yes, it's true that Q1 will still see a drop in inflow. Our
expectation is indeed that in the later part of the year this will reverse. And so far we are
pretty much on track with our targets in terms of inflow. But I think particularly encouraging
is also the good underlying focus -- the focus is still on that obviously.

A - Christophe Boizard

{BIO 15390084 <GO>}

The negative impact on the free capital generation, so I will come back on the breakdown
I have just given and will give you more explanation. So first, I indicated that the
discontinuation of the stop-loss accounted for EUR25 million and you may ask why is there
a net cost on SCR due to the cancellation [ph] of an internal arrangement that within the
stop-loss, we had an external (inaudible) with 22.5% of the stop-loss was placed outside
with the reinsurer and this was done in order to ensure that we had market conditions and
the right pricing. So the fact that we canceled the stop-loss means that at the end we
Page 5 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

FINAL

assume more risk because we take back the share which was previously taken by this
reinsurer. So this EUR25 million, I would say, is therefore -- that's a one-off that will
increase SCR we expect. Then, on the rest of the EUR70 million, so this is directly related
to the quota share this time.
And what the effect we have is, it's a technical effect coming from the Solvency II and it
has to do with the LACDT, as I said in the speech. So the -- what we are doing with the
quota share is that we consider risk from some entities, which are taxpaying entities. So
you have the full benefit of LACDT, but then the risk end up in the Holding, which is not
paying taxes. So you cannot count on the amortization effect of the taxes on future results
because there is no positive tax base so far in the Holding. So I would say this one-off is
here to stay. That's an increase in SCR due to a net loss at the consolidated level on the
LACDT. And by the way, this gives me the opportunity to tell you that we have achieved
Phase 1 on the insurance. We want to go beyond recent this and -- to go beyond this to
have a more positive tax base in the Holding. So this effect will be mitigated, but I am
talking for the future here. This year, this will stay as well the cost of EUR70 million.

Q - Jason Kalamboussis

{BIO 4811408 <GO>}

Thank you very much.

Operator

Bloomberg Transcript

Thank you. Next question from my Robin van den Broek from Mediobanca. Sir, please go
ahead.

Q - Robin van den Broek

{BIO 17002948 <GO>}

Yes. Good morning everybody. First of all, on Slide 13, you provide a EUR397 million of
area for capital transactions and in the slide you specified that's the call debt instrument,
the share buyback and the injection in Asia. But when I add to the call debt instrument and
the share buyback, I would already be well above EUR500 million. So I was just wondering
what the breakdown is on this injection in Asia is?
Second question on your capital generation of EUR148 million from an operating
perspective, that's a fairly large contribution in there from the SCR, so I was just
wondering since you keep your guidance at EUR125 million to EUR130 million per quarter
for the European entities whether you basically see that the negatives of the UK
restructuring and the storm are being offset by that SCR contribution.
And last question is, in your introduction you mentioned that Belgium Life is made mostly
because of lower capital gains, which is true, but if you look at the underlying, so if you
strip out the capital gains in Q1 '18 and Q1 '19, I think you're still looking at EUR36 million
versus EUR53 million. I remember from last year that I think you had EUR10 million of
exceptional investment income in there. So that partly bridges the gap, but still you have a
year-on-year deterioration. So I was just wondering if you can give your views on that.
Thank you.

Page 6 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

A - Bart De Smet

{BIO 16272635 <GO>}

(inaudible)

Q - Robin van den Broek

{BIO 17002948 <GO>}

FINAL

I'm sorry, I cannot hear anything. It is very, very soft.

A - Bart De Smet

{BIO 16272635 <GO>}

Excuse me, can you hear me?

Q - Robin van den Broek

{BIO 17002948 <GO>}

This is a lot better.

A - Bart De Smet

{BIO 16272635 <GO>}

So the first question, the call in Belgium, of course, the $550 million was at 100% as we
only owned 75%. So the impact for AGS was EUR360 million. The capital injection in Asia is
a smaller amount of EUR5 million in the Philippines to follow the growth and the remainder
EUR31 million is share buyback. So it's EUR360 million from the call, EUR5 million
Philippines and EUR31 million share buyback.

Bloomberg Transcript

A - Christophe Boizard

{BIO 15390084 <GO>}

Relating to the capital generation and the decline in SCR noticed in Q1, I think your
observations are correct. The free capital generation is helped by a relatively small SCR
decline in Q1, which is partially seasonal. We also had that last year a few times depending
on when premiums are corrected throughout the year. So that is not necessarily there to
stay throughout the year because you see that our business development, our business
growth is good. And indeed that has been offset, I would say, that benefit as you
indicated by poor weather in Q1, a bit in line with what we saw last year, but also by EUR12
million restructuring costs that we had in the UK, which we hope are not going to be
recurring. So looking forward, you could expect more of flat evolution or a slight increase
in SCR, but then also a better generation of warm [ph] front, of course, weather
permitting that is the correct observation that you made.

A - Hans J. J. De Cuyper

{BIO 17991990 <GO>}

I think on the last question for Belgium, the effect of the capital gain transaction, which
was booked in the technical results due to the nature was actually higher (inaudible) it was
EUR21 million after tax. If we take that into account, our margin before capital gains is
stable even a very slight increase compared to the same quarter last year.

Q - Robin van den Broek

{BIO 17002948 <GO>}

Okay. Thank you very much.

Operator

Page 7 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

Thank you. Next question from Ashik Musaddi from JPMorgan. Please go ahead.

FINAL

Q - Ashik Musaddi

{BIO 15847584 <GO>}

Hi. Good morning, Bart, Christophe. I have a few questions if you can help me on those.
First of all is around M&A, I mean, if I look at Bloomberg, very recently there is speculation
that you're looking at Tranquilidade in Portugal and you've been linked with the CaiFor as
well in Spain. So I mean, it follows your strategy about home market and probably the
fourth new market that you're looking to create. But how should we think about these
from a strategic perspective and as well as from ROI discipline perspective? If you just
remind us your ROI discipline, is it still 11% over the next couple of years or really could it
get relaxed as well, just because there are some opportunities in the market at the
moment, so that's my first one on M&A.
Second thing is, I mean, the numbers are quite messy because of this reinsurance thing.
So can you just give us some clarity as to how much in terms of earnings, how much is one
off ? I mean, things that I can see is, sales campaign, restructuring costs, and then some
extra quota share-related losses. So how much of this combined ratio would you say is a
one-off as well as a how much in the Belgium Life is the sales campaign cost and is it
going to continue for next couple of quarters as well?

Bloomberg Transcript

And the last one is basically Asian earnings, clean, is around EUR100 million for the quarter
ex capital gains. That's way above your guidance of EUR275 million to EUR325 million for
the year. So I mean, shall we still stick with the EUR275 million to EUR325 million, i.e. things
will normalize in few coming quarters or should we just try and be a bit more optimistic on
that? Thank you.

A - Bart De Smet

{BIO 16272635 <GO>}

Okay. Thank you, Ashik. The first question on M&A, so I -- unfortunately, we can only
repeat what we have said at the Investor Day, and is that we in a first place look at
opportunities in markets where we are strong, so being mainly Belgium, Portugal, that we
do not exclude to look to find somewhere a fourth market in Europe -- for fourth market.
But I would say once again it will always be in a disciplined way and we have not realized
some opportunities because we wanted to stay disciplined and we did not want to pay a
price that we believe is not in line with the real, let's say, in opportunity or quality or value
of the potential targets. So, as you know, further than that we never comment on rumors
or on files that appear to be coming or are on the market but that are, let's say, attention
points in Europe, I will stick to this.
The second one, the combined ratio, we are more than convinced that the targets that
we have set to stay below 96% is the one we will achieve. We are fully confident with that.
In terms of specific impacts, one-offs, you could say we have the cost of the restructuring
in UK, but it is not included in the combined ratio, as Christophe mentioned. For the
remainder, you could say, yes, there is the weather impact, but there was weather impact
last year also. The only, let's say, remark I would give in this context is that we were in last
year and mainly in Belgium in a very, very favorable position. So the 93% combined, if I
remember well, of the last year, we don't say it's not possible but that would be a real
great coincidence. But again we believe that we will stay below our target of 96%.
Page 8 of 18



FINAL

Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

The last one, the Asian earnings, remember that also in the past and I though exclude the
impact of capital gains or losses on equity portfolios that in most years, we have behind
us, the fourth quarter has been a weaker quarter in Asia because that's the quarter where
also a lot of expenses are made to start -- to have a good start of the coming years and
that's mainly the case in China. So we don't see a reason at this moment and definitely
not with also the uncertainty on the equity markets to increase our guidance. But overall,
as a group, I would say that the targets that we have or the range in which we believe the
result will be in the course of this year -- at the end of this year between EUR800 million
and EUR900 million group results after excluding RPN(i), which is a bit comparable to an
insurance results of EUR850 million to EUR950 million. We see no reason at all to change
or lower this range. We believe that of course exception made for very unforeseen
circumstances that that will be the range in which we will end at the end of this year.

Q - Ashik Musaddi

{BIO 15847584 <GO>}

Thanks that's very clear. So just going back on the M&A a bit, sorry, I'm coming back to this
because I think it's a very important part of your business model. So, I mean, ROI, is it fair
to say that we should still stick with like 11% ROI hurdle over a two-year period for
developed businesses. Clearly, I'm not talking about Asian businesses because those are
different ballgame altogether, but if you are doing M&A in the developed markets, should
we still stick with 11% ROI over a two-year period?

Bloomberg Transcript

A - Bart De Smet

{BIO 16272635 <GO>}

Well, I would say, that's one of the criteria we've set there. So we will stay to that. Of
course, depending on the country where you are, the risk profile that can be from one
country to another country slight difference in ROE that we -- the ROI that we apply for a
special file and maybe refer slightly to a comment that was made when we entered last
year in the deal in India Non-Life, at that moment the price earnings was considered quite
high around to 40 [ph]. In the meantime based on the full year results of that entity,
Sundaram, it is at this moment 20 [ph] times earnings and if the evolution of the profits
go on within one or two years, it will be 15 times earnings that we paid. So in some
markets you have to be a bit more, let's say, flexible from that side. But we will not for
instance go in Belgium for an acquisition where the return on equity is a 7% to 8%.

Q - Ashik Musaddi

{BIO 15847584 <GO>}

That's very clear. Many thanks for this.

Operator
Thank you. Next question from Farooq Hanif from Credit Suisse. Please go ahead.

Q - Farooq Hanif

{BIO 4780978 <GO>}

Hi there. Good morning. Thank you very much by the way for the explanation in your pre
and post insurance and it was very helpful. So thank you for that. Just three questions;
firstly, I note that your upstream expectation for Asia for 2019 is flat on last year and I'm
just wondering why that's the case given the decent growth and technical liabilities that
you've had. Just if you could explain your thinking behind that. Secondly, could you
Page 9 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

comment a little bit so far about the potential gains or otherwise in Asia in 2Q taking into
account further IFRS can be different from local accounting. And lastly, what can you tell us
about the regulatory, the FCA, review in the UK about the difference in pricing between
existing and new customers. Did you see that as a threat or a problem? Thank you.

Bloomberg Transcript

FINAL

A - Christophe Boizard

{BIO 15390084 <GO>}

Okay. For the first question, the EUR95 million; first of all, it's based on dividends coming
out of China, Thailand, Malaysia. Thailand, Malaysia are overtime more flat. And that's also
in order to keep, let's say, the growth profiles of these companies supported. In China,
the dividend payout is 20%, on the local result, so that's why we receive a relatively high
amount. If you would take the dividend received from China compared to the results we
made on -- we made in IFRS accounting on China, it is even closer to 60%. So every year
decision is taken on the dividend payout, that's 30% and as you can see in the solvency
overview and the solvency of typing live as a public figure. It has slightly decreased now
with 4%, 5% and is at -- if I remember well at 229% end of Q1. So going forward of course
when profits go on up locally, we can expect with the same payout ratio, higher dividends
coming from China.
On the explanation on the potential capital gain in Asia, in Q2. So first let me remind you
that the backdrop of our Asian activity putting aside the capital gain is extremely
favorable. Whole our (inaudible) and we really have satisfactory results everywhere. When
we are left with the volatility of the equity market and you have for sure noticed that the
local indices are very volatile. We were down at the end of last year and we had to book
impairment and we were up by 30% at the end of March and I will come back on this. But
then at this moment with the recent development on the trade war, we are back at plus
20%. So we have lost 10 percentage points compared to end of Q1, so which means that
we have volatility here and volatility is even exacerbated by the fact that we have a
different impairment rule in local, implement rule is, I would say, less flexible -- is more
flexible locally but on our side, we apply our own rule vis-a-vis impairment and we tend to
impair quicker.
So in the capital gain of Q1, part of this is due to the fact that we heavily impaired end of
Q4 of last year and we could take back part of this in Q1. In Q2, we would see what's the
equity market will do, we'll see what our policy will give. But I have to admit that the
visibility is not perfect and volatility is rather high because you know that the equity
allocation in China for instance is quite high, always navigating between 10% and 15%. So I
would say let's monitor and let's see but we are still at plus 20% vis-a-vis end of
December of last year, which gives a decent margin for the future. But it cannot be
(inaudible)

Q - Farooq Hanif

{BIO 4780978 <GO>}

If I just following up the fact that there's been a recovery year-to-date could potentially, in
my view, I think lessen the downside risk on impairment. Would you agree with that in 3Q,
sorry in 2Q?

A - Bart De Smet

{BIO 16272635 <GO>}

Page 10 of 18



FINAL

Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

Yes, maybe a few words on the FCA pricing review in UK and particularly you refer to the
price discrimination between new business and renewal. So, yes, there is some legislation
or some paper that's going to be published by the FCA. We are aware obviously of
discussions between the FCA and the British Association of Insurance. Now, is this good
news or bad news for us, I think it's fair to say that we have our own fair pricing framework
quite a while in place. So I would say that we would be more on the positive side of the
equation compared to our peers. This is obviously a market phenomenon, so the market
will adapt to the new rules for us. For now, I would just keep it as a neutral item. Obviously,
it has also some possibilities. I think by June, July we'll know a bit more.

Q - Farooq Hanif

{BIO 4780978 <GO>}

Okay. That's very helpful. Thank you so much.

Operator
Thank you. Next question from Bart Jooris from Banque Degroof Petercam. Sir, please go
ahead.

Bloomberg Transcript

Q - Bart Jooris

{BIO 3470300 <GO>}

Yes. Hi. Thank you for taking my questions. If I -- you already touched on this Bart, but if I
could continue a little bit on the combined ratios in Belgium, we saw increases in an all
business lines. So there is only a weather impact of this. So what we should see as the
new normal going forward than the same a little bit we saw a slight increase there's still a
very good combined ratio in Central Europe, is that also a new normal? And then
regarding to the UK, if we add back the reinsurance EUR3 million and the restructuring of
EUR12 million, it's EUR26 million, if we do that times three and we add the profit of this
year, you're already on the top of your guided range. Do you stick to that range?

A - Bart De Smet

{BIO 16272635 <GO>}

Okay. Maybe for the combined ratio, Belgium, I will leave it to Hans to give a bit more
detail. Hans?

A - Hans J. J. De Cuyper

{BIO 17991990 <GO>}

Well, I think that the prime effect is indeed as we said the weather effect in the Non-Life
business for a full 10%. If I zoom in on the detail, we see a slight deterioration if we
exclude the weather impact on Accident and Health, but nothing really to look to worry
about mainly in workmen's compensation. We see more -- a slight deterioration in Motor,
but overall the Motor business for us is far within the 96% target. We see actually
excluding weather a nice further improvement in Household and Fire. So I think the story is
a little bit mixed. If we look at the numbers excluding weather impact that we have no
concerns at this stage on the 96% ambition. Of course, for the remainder of the year, the
impact of reinsurance for additional weather effects that might happen of course will
come into play. So you can definitely not extrapolate the weather impact for the full year.

A - Bart De Smet

{BIO 16272635 <GO>}

Page 11 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

FINAL

Okay. And then on UK, you rightly indicated that if we would take out restructuring cost
and add the reinsurance that we are above this EUR11 million reported, we stick to our
guidance given earlier of target being EUR70 million and EUR90 million. But as the EUR3
million this quarter part of it will be recognized under the reinsurance segment. But if you
look through the AGS results coming out of the UK, you could indeed keep that EUR70
million to EUR90 million that we indicated earlier at the full year results scope.

Q - Bart Jooris

{BIO 3470300 <GO>}

But probably more on the top of the range, right?

A - Bart De Smet

{BIO 16272635 <GO>}

If we can exceed the targets we give we will never let it stay apart. So but take also the
overall indication I gave that we are quite confident again not excluding, really unforeseen
would say, world's issues that we will see -- the year between that EUR800 million to
EUR900 million group results, -- EUR850 million to EUR950 million insurance results;
whether it will be on the lower, higher or medium end, that's something I think where we
probably will be able to give a bit more feeling further in the year.

Q - Bart Jooris

{BIO 3470300 <GO>}

Okay. One small detail on that, is there any update on the Ogden rate of evolution?

Bloomberg Transcript

A - Bart De Smet

{BIO 16272635 <GO>}

On Ogden, everybody awaits the first weeks of August as the date and that will be
published. But as with many things in the UK, you never know.

Q - Bart Jooris

{BIO 3470300 <GO>}

Okay. Thank you very much.

Operator
Thank you. Next question from Albert Ploegh from ING. Sir, please go ahead.

Q - Albert Ploegh

{BIO 3151309 <GO>}

Yes. Good morning. Thank you for taking my questions. I've got basically two. One is on
the earnings bridge in Asia from Q1 last year to Q1 this year. To understand a bit better
what is the true operating underlying performance? Q1 last year, I think, there were some
favorable impact from interest rate movements and also a quite low, let's say, expenses
rates to commercial sales. Clearly this year, the capital gains are higher but to better
understand the bridge between those two periods. And the second question is also a bit
related to on capital gains. And looking at Belgium Life, it was well known that it would be
low in Q1 this year. Can you say something on the budget for the full year? I know it's
always a bit difficult to talk about budgets for capital gains but maybe in relation to at least
the real estate capital gains that you expect mainly? Thank you.

Page 12 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

FINAL

A - Christophe Boizard

{BIO 15390084 <GO>}

On the first question, so the comparison Asia last year and this year, I would indicate that
the main difference is the higher net capital gains. If you look through slides, sorry Slide 5
or 6, I think is -- sorry 19, you'll see that last year, we had EUR25 million capital gains, this
year EUR49 million, so it's plus EUR24 million and the net result goes up with EUR23
million. So what you would see is that the end results we had two, three years ago in
Philippines and in Vietnam are on the right path. In Vietnam, we are almost breakeven.
Philippines will take a bit more time, but we are not far from a breakeven, I would say,
within one, two years. And then there was on reevaluation of reserves in China, there was
a minimal impact, I think, something like EUR5 million. So that's some of the explanations.
But the big difference is lower capital gains.

Q - Albert Ploegh

{BIO 3151309 <GO>}

Okay. Thank you.

Operator
Thanks. Your next question from Matthias De Wit from Kempen. Please go ahead.

Bloomberg Transcript

A - Christophe Boizard

{BIO 15390084 <GO>}

Sorry you still -- would you still like to get some feedback on the capital gains in Belgium. I
think you had the second follow up question. There were -- I don't think we will give the
full budget numbers for the year, but what I can tell you is we are quite on track of what is
concerned the capital gains on equities. I think we are there within the ambition level
quarter on quarter. And real estate, there are few transactions in the pipeline, which were
scheduled and at this moment they're also fully on track. So we still keep our ambition on
the operating margin towards the end of the year, which is also within the targets of the
group.

Q - Albert Ploegh

{BIO 3151309 <GO>}

Okay, clear.

Operator
Sorry, now, next question from Matthias De Wit from Kempen. Sir, please go ahead.

Q - Matthias De Wit

{BIO 15856815 <GO>}

Good morning. I've got two questions, please. First is on capital generations. I could just
come back to the operational SCR movement the decline of EUR30 million, you
mentioned seasonal items, but is there anything else that you can highlight because I
would have expected an increase given that the book grew during the quarter and also
the allocation for risky assets increased. So just wonder if part of that risky impact is
captured by the market (inaudible), if you could confirm that please.

Page 13 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

FINAL

And just to continue on capital generation, we've seen quite strong decrease in risk free
rate and credit [ph] during the quarter. So is there anything you can say on how sensitive
your capital generation is to this macro movement? And then just a second question is on
taxation. What should we expect in terms of the effective tax rate following the reforms
we've seen in Belgium and also taking into account the impact of the reinsurance -internal reinsurance, which could be beneficial? Thank you.

A - Christophe Boizard

{BIO 15390084 <GO>}

Okay, Matthias, thank you for your questions. Okay. I can indeed only repeat that the main
aspect is seasonality, and if you look at the movement in SCR, of course on the quarter,
it's always exaggerated in the free capital generation because in overall it's only a small
fluctuation percentage wise on a EUR4 billion. But indeed to your point on why the growth
that we see is not reflecting directly in some increase in SCR, now one of the points is that
a substantial component in the growth in the first quarter and Bart indicated that is due to
very strong growth in unit-linked lines of business. And, of course, there is little capital
consumption related to that. So that kind of offsets what I would say you normally would
expect if you see the top line development.

Bloomberg Transcript

Related to macro movements and sensitivities on free capital generation, of course I have
to refer you to the sensitivity tables which we updated in this presentation and I think they
are on Page 58, you'll find the updated sensitivities at least on the solvency ratio but, we
break them up on SCR and own funds impact. So that should give you some indications
there, how these things impact the free capital generation.
Now specifically for this quarter, because I noted in some of the comments that are
coming out of the analyst reports already, that people were to some extent surprised by
the high impact of the market component for the quarter because indeed, market impact
was around 5% in the solvency ratio. And if you compare the movement on the yield
curve, because actually it is all related to yield curve movements, to the last quarter of last
year where we also saw the yield curve come down a bit.
Yield curves on average last year had a lateral move of about between 10 bps and 15 bps.
This year, however, it is more the long hand that came down, so it's more a flattening of
the curve and in fact on the relevant segment, the impact was around 30 bps. So it
actually is double the impact of we saw in last quarter. And if you then look at the table on
Page 58 and compare that with the sensitivities that have been given on the yield curve,
down 50 bps would have an impact of 15% that brings that very much in line what we saw
happening in the first quarter this year. So I have the feeling that by now our sensitivities
that we give, of course, they're based on the end of year solvency, give a good indication
of the macroeconomic impact that you can expect also on SCR as well as own funds and
on some free capital generation.

Q - Matthias De Wit

{BIO 15856815 <GO>}

Thank you. And the tax thing?

A - Christophe Boizard

{BIO 15390084 <GO>}
Page 14 of 18



FINAL

Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

On the tax following the reinsurance, so I don't want to spend too much time after -- on
the three months and one quarter because we are not in a very favorable position, why?
Because in my speech I told you that what we booked is an initial loss of EUR12 million,
which is you will guess this not the long-term expectation, why, because if we have a loss
at the Holding level, it's counterproductive on the tax rate, which means that we have
positive impact on the tax paying entity, and of course, I am thinking of AG. So on Q1, the
result of the reinsurance is more tax for Belgium unfortunately, and at the Holding level,
we have a loss which cannot be offset by any positive tax base.
So we are not in the -- what we expect, but I'd like to mention the fact that we have oneoff costs, setup costs but not what we expect. We know that with the absence of
(inaudible) Belgium, the positive result at the Holding level will build up progressively over
several years, and that in the future, we will have a decrease tax rate at group level but
not at the end of Q1 unfortunately. But this is temporary and please note that there is no
tax return based on the quarter. So these are accounting entries, as far as cash is
concerned, it will be an annual tax return at the end of the year and my expectation is that
the net profit of the quota share at the Holding level will give a better image at the end of
the year. Thank you.

Q - Matthias De Wit

{BIO 15856815 <GO>}

Okay. Thank you.

Operator

Bloomberg Transcript

Thank you. Next question from Jason Kalamboussis from KBC Securities. Please go ahead.

Q - Jason Kalamboussis

{BIO 4811408 <GO>}

Yes. Hi. Just quick follow-up questions. The one is on the M&A that was asked earlier. I just
wanted just to ask, I mean, Portugal that's fine that's in line with what you got, but when
you're looking at the new country in Europe, I thought that your preference would have
been less to be opportunistic and more to look at countries like Italy where you already
know the market rather than entering for example a new country like Spain. If you have
any thoughts I would appreciate that.
And the second thing is on reinsurance on the quota share. You have given us very helpful
explanations in April with a webinar, but are you confident that there is no way that in the
future there could be an issue on how you have structured it. I mean, you have taken all
the precautions basically so that every unit is independent and can voice its opinion and
basically said the quota share in an agreement if you want with the reinsurance theme,
but are you confident that in the future there is no way that there will be an issue from the
taxman in a certain way either general to spending a lot of time and that the benefits
somewhere in the future could run into an issue.

A - Bart De Smet

{BIO 16272635 <GO>}

Okay. Jason, the first question, again, we don't comment on the rumors as. So when we
said that we might look to a fourth market to find a fourth core activity as far as I know we
Page 15 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

FINAL

excluded explicitly markets like Germany and France because too big for us. We also on
the specific question mentioned that we believe that our added value in the Netherlands
would be minor knowing that there are three, four big players that have advantages and
that's it. So we didn't mention specifically or exclude specifically other countries. So no real
concrete things that we can share or we'll share it with the outside world.

Q - Jason Kalamboussis

{BIO 4811408 <GO>}

Okay. So if I may -- on this one you don't have a preference for a market like Italy. It is
basically for you every country, it will depend on the opportunities and what you see
coming in front of you?

A - Bart De Smet

{BIO 16272635 <GO>}

Bloomberg Transcript

I could say, and then don't take it as whatever indication, we have experience in Italy. We
have had as a group a lot of experience in the Netherlands. We also have had the
experience with CaiFor for a long time ago in Spain. So I think of course that's an element
in Europe we will look at whether we have some good knowledge of the markets, but
next to that we don't have a blacklist of all these excluded. We don't have -- we have of
course some areas that might be preferential but we -- for the reasons you know we will
not share them with the outside world.
On the potential issue with the tax authorities coming from this internal quota share
arrangements. So, as you can get, that was one of our key points in the file when we
studied the file and we have studied the file for quite a while now. So it was well captured
since the beginning, I think that we have (inaudible) why? Because we had really
(inaudible) but a very serious discussion about the conditions in order to ensure that
market conditions are within these context and I will take the example of Belgium;
Belgium (inaudible) a specific reinsurance broker to help them to have the market and we
had our own reinsurance broker so it means that two insurance brokers were in the group
and I can tell you we have all the meetings we had, we've hold the exchange of
(inaudible) for negotiation, which was a long one. We cannot say but it was something
completely driven by the Holding. It was, I can -- I'm 100% sure this real market and length
transaction. In any case, the tax authorities are consulted. We are in the process of
discussing tax ruling, and if we obtain a tax ruling, this will remove all the risk for the future.

Q - Jason Kalamboussis

{BIO 4811408 <GO>}

When do you expect to get that tax ruling?

A - Bart De Smet

{BIO 16272635 <GO>}

On that side, but I really feel confident about the strength of our tax authority. These are
things which are known in the market. If you go to the UK for instance that is very
common, this kind of protection arrangement at even much larger scale. So frankly it
should be okay. But in any case we will have the formal feedback from the tax authority.

Q - Jason Kalamboussis

{BIO 4811408 <GO>}

Page 16 of 18



Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

Yes, I appreciate that you have had -- there have been a very thorough action in each
country to do it, but just when you are going to have the tax ruling that kind of will free up
if you want any residual risk even if not this is very remote.

FINAL

A - Bart De Smet

{BIO 16272635 <GO>}

If we free up, and you risk because once the tax ruling is obtained, the physical
administration cannot comeback on what the tax ruling states.

Q - Jason Kalamboussis

{BIO 4811408 <GO>}

Yes, but the tax ruling, when is that in place?

A - Bart De Smet

{BIO 16272635 <GO>}

It's under way. So there are some delays. So we have to wait for some months but the
outcome will be known before the end of the year.

Q - Jason Kalamboussis

{BIO 4811408 <GO>}

Superb. Thank you very much. Very helpful.

Operator

Bloomberg Transcript

Thank you. We don't have any more questions for the moment. (Operator Instructions) As
there are no further questions, I would like to return the conference call back to the
speakers.

A - Bart De Smet

{BIO 16272635 <GO>}

Okay, ladies and gentlemen, thank you for your interesting and strong questions. To end
this call, let me summarize the main conclusions. Our net result was in line with the strong
one delivered last year with the exceptionally high result in Asia, offsetting the lower
capital gains in Belgium. We enjoyed a solid growth across most of the segments
including an exceptional sales momentum in Belgium. We generated a strong operational
free capital of EUR148 million. We reconfirmed our belief of EUR800 million to EUR900
million, net group profit for the whole year. With this I would bring this call to an end. Do
not hesitate to contact our Investor Relations team should you have outstanding
questions. Thanks for your time and I would like to wish you a very nice day. Thank you.

Operator
Ladies and gentlemen, this concludes today's conference call. Thank you very much for
attending. You may now disconnect your lines.

This transcript may not be 100 percent accurate and may contain misspellings and other
inaccuracies. This transcript is provided "as is", without express or implied warranties of
any kind. Bloomberg retains all rights to this transcript and provides it solely for your
Page 17 of 18



personal, non-commercial use. Bloomberg, its suppliers and third-party agents shall
have no liability for errors in this transcript or for lost profits, losses, or direct, indirect,
incidental, consequential, special or punitive damages in connection with the
furnishing, performance or use of such transcript. Neither the information nor any
opinion expressed in this transcript constitutes a solicitation of the purchase or sale of
securities or commodities. Any opinion expressed in the transcript does not necessarily
reflect the views of Bloomberg LP.  COPYRIGHT 2022, BLOOMBERG LP. All rights
reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

Bloomberg Transcript

FINAL

Company N ame: Ageas SA/N V
Company Ticker: AGS BB Equity
Date: 2019-05-15

Page 18 of 18

